Different Gene Expression Patterns of IL-1 Family Members in Parkinson's Disease: Results from Bayesian Regression Model
-
Negin Jafariaghdam
,
Majid Khoshmirsafa
,
Alireza Zamani
,
Elahe Talebi-Ghane
,
Shadi Moradi
,
Faezeh Shahba
,
Mehrdokht Mazdeh
,
Mohammad Mahdi Eftekharian
Abstract
Parkinson's disease, the second most prevalent neurodegenerative disorder lacking a recognized etiology, is influenced by oxidative stress and alterations in inflammatory cytokine levels. This study aimed to investigate the expression levels of Interleukin(IL)1 receptor accessory protein (IL-1RAcP), IL1β, IL1α, IL33, and IL36 genes in blood cells and serum IL-1β levels in Parkinson's disease patients compared to healthy controls (HCs).I
n this case-control study, 44 Parkinson's disease patients and 44 age- and sex-matched HCs were included. Gene expression levels were assessed using Quantitative Real-time PCR, and serum IL-1β levels were measured via enzyme-linked immunosorbent assay. Advanced statistical analyses using the Bayesian regression model in R software were employed.
Parkinson's disease patients exhibited elevated expression levels of IL-1RAcP and IL1β genes but decreased levels of IL1α, IL33, and IL36 compared to HCs. Age-based differences were not significant. Regarding gender, IL33 transcript levels were significantly higher in males, and serum IL-1β levels were increased in patients. Subgroup analysis by gender indicated alterations in IL1β and IL-1RAcP expression in both genders, while IL1α, IL33, and IL36 showed reduced expression only in males. Remarkably, only female patients displayed significantly higher serum IL-1β levels than female HCs.
These findings suggest that dysregulation of immune-related factors plays a crucial role in Parkinson's disease.
1. Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med. 2020;36(1):1-12.
2. Zeng XS, Geng WS, Jia JJ, Chen L, Zhang PP. Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease. Front Aging Neurosci. 2018;10:109.
3. Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22(11):657-73.
4. Villumsen M, Aznar S, Pakkenberg B, Jess T, Brudek T. Inflammatory bowel disease increases the risk of Parkinson's disease: a Danish nationwide cohort study 1977-2014. Gut. 2019;68(1):18-24.
5. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10(2):89-102.
6. Fields JK, Günther S, Sundberg EJ. Structural Basis of IL-1 Family Cytokine Signaling. Front Immunol. 2019;10:1412.
7. Zettergren A, Höglund K, Kern S, Thorvaldsson V, Johan Skoog M, Hansson O, et al. Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. Sci Rep. 2019;9(1):2460.
8. Ramanan VK, Risacher SL, Nho K, Kim S, Shen L, McDonald BC, et al. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer’s disease implicates microglial activation gene IL1RAP. Brain. 2015;138(10):3076-88.
9. Jiang T, Zheng T, Li W, Liu N, Wang M. IL-33/ST2 signaling pathway and Alzheimer's Disease: A systematic review and meta-analysis. Clin Neurol Neurosurg. 2023:107773.
10. Liang C-S, Su K-P, Tsai C-L, Lee J-T, Chu C-S, Yeh T-C, et al. The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease. Alzheimers Res Ther. 2020;12(1):1-9.
11. Masoumi J, Vakilian A, Sayadi A, Shekari N, Khorramdelazad H. Assessing the gene expression of interleukin-36 in Alzheimer's patients. Gene Reports. 2020;21:100823.
12. Zarezadeh Mehrabadi A, Aghamohamadi N, Khoshmirsafa M, Aghamajidi A, Pilehforoshha M, Massoumi R, Falak R. The roles of interleukin-1 receptor accessory protein in certain inflammatory conditions. Immunology. 2022;166(1):38-46.
13. Gabryelska A, Kuna P, Antczak A, Białasiewicz P, Panek M. IL-33 mediated inflammation in chronic respiratory diseases—understanding the role of the member of IL-1 superfamily. Front Immunol. 2019;10:692.
14. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479-90.
15. Sun Y, Wen Y, Wang L, Wen L, You W, Wei S, et al. Therapeutic opportunities of interleukin-33 in the central nervous system. Front Immunol. 2021;12:654626.
16. Walsh PT, Fallon PG. The emergence of the IL‐36 cytokine family as novel targets for inflammatory diseases. Ann N Y Acad Sci. 2018;1417(1):23-34.
17. Yi G, Ybe JA, Saha SS, Caviness G, Raymond E, Ganesan R, et al. Structural and functional attributes of the interleukin-36 receptor. Journal of Biological Chemistry. 2016;291(32):16597-609.
18. Yuan Z-C, Xu W-D, Liu X-Y, Liu X-Y, Huang A-F, Su L-C. Biology of IL-36 signaling and its role in systemic inflammatory diseases. Front Immunol. 2019;10:2532.
19. Rao X, Huang X, Zhou Z, Lin X. An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath. 2013;3(3):71-85.
20. Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Transl Neurodegener. 2015;4:19.
21. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol. 1988;24(4):574-6.
22. Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflammation. 2008;5:8.
23. Choudhury SP, Bano S, Sen S, Suchal K, Kumar S, Nikolajeff F, et al. Altered neural cell junctions and ion-channels leading to disrupted neuron communication in Parkinson’s disease. npj Parkinson Disease. 2022;8(1):66.
24. Lee Y, Lee S, Chang SC, Lee J. Significant roles of neuroinflammation in Parkinson's disease: therapeutic targets for PD prevention. Arch Pharm Res. 2019;42(5):416-25.
25. Berglöf E, Andre R, Renshaw BR, Allan SM, Lawrence CB, Rothwell NJ, Pinteaux E. IL-1Rrp2 expression and IL-1F9 (IL-1H1) actions in brain cells. J Neuroimmunol. 2003;139(1-2):36-43.
26. Lin CC, Edelson BT. New Insights into the Role of IL-1β in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. J Immunol. 2017;198(12):4553-60.
27. Joshi AU, Minhas PS, Liddelow SA, Haileselassie B, Andreasson KI, Dorn GW, 2nd, Mochly-Rosen D. Fragmented mitochondria released from microglia trigger A1 astrocytic response and propagate inflammatory neurodegeneration. Nat Neurosci. 2019;22(10):1635-48.
28. Karpenko MN, Vasilishina AA, Gromova EA, Muruzheva ZM, Miliukhina IV, Bernadotte A. Interleukin-1β, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-α levels in CSF and serum in relation to the clinical diversity of Parkinson's disease. Cell Immunol. 2018;327:77-82.
29. Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y. Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis. JAMA Neurol. 2016;73(11):1316-24.
30. Rolli-Derkinderen M, Leclair-Visonneau L, Bourreille A, Coron E, Neunlist M, Derkinderen P. Is Parkinson's disease a chronic low-grade inflammatory bowel disease? J Neurol. 2020;267(8):2207-13.
31. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Bienfait K, et al. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics. 2010;51(6):474-9.
32. Kıçık A, Tüzün E, Erdoğdu E, Bılgıç B, Tüfekçıoğlu Z, Öztürk-Işik E, et al. Neuroinflammation Mediators are Reduced in Sera of Parkinson's Disease Patients with Mild Cognitive Impairment. Noro Psikiyatr Ars. 2020;57(1):15-7.
33. Koziorowski D, Tomasiuk R, Szlufik S, Friedman A. Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. Cytokine. 2012;60(3):762-6.
34. Dursun E, Gezen-Ak D, Hanağası H, Bilgiç B, Lohmann E, Ertan S, et al. The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease. J Neuroimmunol. 2015;283:50-7.
35. Yoshida T, Shiroshima T, Lee SJ, Yasumura M, Uemura T, Chen X, et al. Interleukin-1 receptor accessory protein organizes neuronal synaptogenesis as a cell adhesion molecule. J Neurosci. 2012;32(8):2588-600.
36. Brikos C, Wait R, Begum S, O'Neill LA, Saklatvala J. Mass spectrometric analysis of the endogenous type I interleukin-1 (IL-1) receptor signaling complex formed after IL-1 binding identifies IL-1RAcP, MyD88, and IRAK-4 as the stable components. Mol Cell Proteomics. 2007;6(9):1551-9.
37. Smith DE, Lipsky BP, Russell C, Ketchem RR, Kirchner J, Hensley K, et al. A central nervous system-restricted isoform of the interleukin-1 receptor accessory protein modulates neuronal responses to interleukin-1. Immunity. 2009;30(6):817-31.
38. Ramanan VK, Risacher SL, Nho K, Kim S, Shen L, McDonald BC, et al. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. Brain. 2015;138(Pt 10):3076-88.
39. Xiong Z, Thangavel R, Kempuraj D, Yang E, Zaheer S, Zaheer A. Alzheimer's disease: evidence for the expression of interleukin-33 and its receptor ST2 in the brain. J Alzheimers Dis. 2014;40(2):297-308.
40. Jafarzadeh A, Mahdavi R, Jamali M, Hajghani H, Nemati M, Ebrahimi HA. Increased Concentrations of Interleukin-33 in the Serum and Cerebrospinal Fluid of Patients with Multiple Sclerosis. Oman Med J. 2016;31(1):40-5.
41. Christophi GP, Gruber RC, Panos M, Christophi RL, Jubelt B, Massa PT. Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients. Clin Immunol. 2012;142(3):308-19.
42. Kempuraj D, Selvakumar GP, Zaheer S, Thangavel R, Ahmed ME, Raikwar S, et al. Cross-Talk between Glia, Neurons and Mast Cells in Neuroinflammation Associated with Parkinson's Disease. J Neuroimmune Pharmacol. 2018;13(1):100-12.
43. Xu J, He X, Xu Y, Chen X, Li M, Zhang L, et al. Characteristics of systemic inflammation and brain iron deposition in Parkinson's disease patients. Ann Clin Transl Neurol. 2022;9(3):276-85.
44. Kempuraj D, Khan MM, Thangavel R, Xiong Z, Yang E, Zaheer A. Glia maturation factor induces interleukin-33 release from astrocytes: implications for neurodegenerative diseases. J Neuroimmune Pharmacol. 2013;8(3):643-50.
45. Chapuis J, Hot D, Hansmannel F, Kerdraon O, Ferreira S, Hubans C, et al. Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Mol psychiatry. 2009;14(11):1004-16.
46. Fu AK, Hung KW, Yuen MY, Zhou X, Mak DS, Chan IC, et al. IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline. Proc Natl Acad Sci U S A. 2016;113(19):E2705-13.
47. Xu J, He X, Xu Y, Chen X, Li M, Zhang L, et al. Characteristics of systemic inflammation and brain iron deposition in Parkinson's disease patients. Ann Clin Transl Neurol. 2022;9(3):276-85.
48. Lopetuso L, Chowdhry S, Pizarro T. Opposing Functions of Classic and Novel IL-1 Family Members in Gut Health and Disease. Front Immunol. 2013;4.
49. Zhu Y, Yuan M, Liu Y, Yang F, Chen WZ, Xu ZZ, et al. Association between inflammatory bowel diseases and Parkinson's disease: systematic review and meta-analysis. Neural Regen Res. 2022;17(2):344-53.
50. Harusato A, Abo H, Ngo VL, Yi SW, Mitsutake K, Osuka S, et al. IL-36γ signaling controls the induced regulatory T cell-Th9 cell balance via NFκB activation and STAT transcription factors. Mucosal Immunol. 2017;10(6):1455-67.
51. Li Q, Liu S, Li L, Ji X, Wang M, Zhou J. Spinal IL-36γ/IL-36R participates in the maintenance of chronic inflammatory pain through astroglial JNK pathway. Glia. 2019;67(3):438-51.
52. Alsahebfosoul F, Jahanbani-Ardakani H, Ghavimi R, Sedaghat N, Etemadifar M. Serum level of interleukin 36 in patients with multiple sclerosis. J Immunoassay Immunochem. 2018;39(5):558-64.
53. Hill MA, Gammie SC. Alzheimer’s disease large-scale gene expression portrait identifies exercise as the top theoretical treatment. Sci Reports. 2022;12(1):17189.
54. Liu G, Fiala M, Mizwicki MT, Sayre J, Magpantay L, Siani A, et al. Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am J Neurodegener Dis. 2012;1(1):60-74.
55. Tang J, Zeng X, Yang J, Zhang L, Li H, Chen R, et al. Expression and Clinical Correlation Analysis Between Repulsive Guidance Molecule a and Neuromyelitis Optica Spectrum Disorders. Front Immunol. 2022;13.
56. Moradi S, Zamani A, Mazdeh M, Ramezani M, Komaki A, Talebi-Ghane E, Eftekharian MM. An inclusive study on cytokine gene expression in Parkinson's disease: Advanced analysis using Bayesian regression model. Hum Immunol. 2023;84(2):123-9.
57. Fischer B, Kübelbeck TV, Kolb AL, Ringen J, Waisman A, Wittmann M, et al. IL-17A-driven psoriasis is critically dependent on IL-36 signaling. Front Immunol.14:1256133.
58. Mercurio L, Failla CM, Capriotti L, Scarponi C, Facchiano F, Morelli M, et al. Interleukin (IL)-17/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses. PLoS One. 2020;15(4):e0222969.
59. Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, Onofrj M. Peripheral cytokines profile in Parkinson's disease. Brain Behav Immun. 2009;23(1):55-63.
2. Zeng XS, Geng WS, Jia JJ, Chen L, Zhang PP. Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease. Front Aging Neurosci. 2018;10:109.
3. Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22(11):657-73.
4. Villumsen M, Aznar S, Pakkenberg B, Jess T, Brudek T. Inflammatory bowel disease increases the risk of Parkinson's disease: a Danish nationwide cohort study 1977-2014. Gut. 2019;68(1):18-24.
5. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10(2):89-102.
6. Fields JK, Günther S, Sundberg EJ. Structural Basis of IL-1 Family Cytokine Signaling. Front Immunol. 2019;10:1412.
7. Zettergren A, Höglund K, Kern S, Thorvaldsson V, Johan Skoog M, Hansson O, et al. Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. Sci Rep. 2019;9(1):2460.
8. Ramanan VK, Risacher SL, Nho K, Kim S, Shen L, McDonald BC, et al. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer’s disease implicates microglial activation gene IL1RAP. Brain. 2015;138(10):3076-88.
9. Jiang T, Zheng T, Li W, Liu N, Wang M. IL-33/ST2 signaling pathway and Alzheimer's Disease: A systematic review and meta-analysis. Clin Neurol Neurosurg. 2023:107773.
10. Liang C-S, Su K-P, Tsai C-L, Lee J-T, Chu C-S, Yeh T-C, et al. The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease. Alzheimers Res Ther. 2020;12(1):1-9.
11. Masoumi J, Vakilian A, Sayadi A, Shekari N, Khorramdelazad H. Assessing the gene expression of interleukin-36 in Alzheimer's patients. Gene Reports. 2020;21:100823.
12. Zarezadeh Mehrabadi A, Aghamohamadi N, Khoshmirsafa M, Aghamajidi A, Pilehforoshha M, Massoumi R, Falak R. The roles of interleukin-1 receptor accessory protein in certain inflammatory conditions. Immunology. 2022;166(1):38-46.
13. Gabryelska A, Kuna P, Antczak A, Białasiewicz P, Panek M. IL-33 mediated inflammation in chronic respiratory diseases—understanding the role of the member of IL-1 superfamily. Front Immunol. 2019;10:692.
14. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479-90.
15. Sun Y, Wen Y, Wang L, Wen L, You W, Wei S, et al. Therapeutic opportunities of interleukin-33 in the central nervous system. Front Immunol. 2021;12:654626.
16. Walsh PT, Fallon PG. The emergence of the IL‐36 cytokine family as novel targets for inflammatory diseases. Ann N Y Acad Sci. 2018;1417(1):23-34.
17. Yi G, Ybe JA, Saha SS, Caviness G, Raymond E, Ganesan R, et al. Structural and functional attributes of the interleukin-36 receptor. Journal of Biological Chemistry. 2016;291(32):16597-609.
18. Yuan Z-C, Xu W-D, Liu X-Y, Liu X-Y, Huang A-F, Su L-C. Biology of IL-36 signaling and its role in systemic inflammatory diseases. Front Immunol. 2019;10:2532.
19. Rao X, Huang X, Zhou Z, Lin X. An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath. 2013;3(3):71-85.
20. Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Transl Neurodegener. 2015;4:19.
21. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol. 1988;24(4):574-6.
22. Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflammation. 2008;5:8.
23. Choudhury SP, Bano S, Sen S, Suchal K, Kumar S, Nikolajeff F, et al. Altered neural cell junctions and ion-channels leading to disrupted neuron communication in Parkinson’s disease. npj Parkinson Disease. 2022;8(1):66.
24. Lee Y, Lee S, Chang SC, Lee J. Significant roles of neuroinflammation in Parkinson's disease: therapeutic targets for PD prevention. Arch Pharm Res. 2019;42(5):416-25.
25. Berglöf E, Andre R, Renshaw BR, Allan SM, Lawrence CB, Rothwell NJ, Pinteaux E. IL-1Rrp2 expression and IL-1F9 (IL-1H1) actions in brain cells. J Neuroimmunol. 2003;139(1-2):36-43.
26. Lin CC, Edelson BT. New Insights into the Role of IL-1β in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. J Immunol. 2017;198(12):4553-60.
27. Joshi AU, Minhas PS, Liddelow SA, Haileselassie B, Andreasson KI, Dorn GW, 2nd, Mochly-Rosen D. Fragmented mitochondria released from microglia trigger A1 astrocytic response and propagate inflammatory neurodegeneration. Nat Neurosci. 2019;22(10):1635-48.
28. Karpenko MN, Vasilishina AA, Gromova EA, Muruzheva ZM, Miliukhina IV, Bernadotte A. Interleukin-1β, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-α levels in CSF and serum in relation to the clinical diversity of Parkinson's disease. Cell Immunol. 2018;327:77-82.
29. Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y. Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis. JAMA Neurol. 2016;73(11):1316-24.
30. Rolli-Derkinderen M, Leclair-Visonneau L, Bourreille A, Coron E, Neunlist M, Derkinderen P. Is Parkinson's disease a chronic low-grade inflammatory bowel disease? J Neurol. 2020;267(8):2207-13.
31. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Bienfait K, et al. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics. 2010;51(6):474-9.
32. Kıçık A, Tüzün E, Erdoğdu E, Bılgıç B, Tüfekçıoğlu Z, Öztürk-Işik E, et al. Neuroinflammation Mediators are Reduced in Sera of Parkinson's Disease Patients with Mild Cognitive Impairment. Noro Psikiyatr Ars. 2020;57(1):15-7.
33. Koziorowski D, Tomasiuk R, Szlufik S, Friedman A. Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. Cytokine. 2012;60(3):762-6.
34. Dursun E, Gezen-Ak D, Hanağası H, Bilgiç B, Lohmann E, Ertan S, et al. The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease. J Neuroimmunol. 2015;283:50-7.
35. Yoshida T, Shiroshima T, Lee SJ, Yasumura M, Uemura T, Chen X, et al. Interleukin-1 receptor accessory protein organizes neuronal synaptogenesis as a cell adhesion molecule. J Neurosci. 2012;32(8):2588-600.
36. Brikos C, Wait R, Begum S, O'Neill LA, Saklatvala J. Mass spectrometric analysis of the endogenous type I interleukin-1 (IL-1) receptor signaling complex formed after IL-1 binding identifies IL-1RAcP, MyD88, and IRAK-4 as the stable components. Mol Cell Proteomics. 2007;6(9):1551-9.
37. Smith DE, Lipsky BP, Russell C, Ketchem RR, Kirchner J, Hensley K, et al. A central nervous system-restricted isoform of the interleukin-1 receptor accessory protein modulates neuronal responses to interleukin-1. Immunity. 2009;30(6):817-31.
38. Ramanan VK, Risacher SL, Nho K, Kim S, Shen L, McDonald BC, et al. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. Brain. 2015;138(Pt 10):3076-88.
39. Xiong Z, Thangavel R, Kempuraj D, Yang E, Zaheer S, Zaheer A. Alzheimer's disease: evidence for the expression of interleukin-33 and its receptor ST2 in the brain. J Alzheimers Dis. 2014;40(2):297-308.
40. Jafarzadeh A, Mahdavi R, Jamali M, Hajghani H, Nemati M, Ebrahimi HA. Increased Concentrations of Interleukin-33 in the Serum and Cerebrospinal Fluid of Patients with Multiple Sclerosis. Oman Med J. 2016;31(1):40-5.
41. Christophi GP, Gruber RC, Panos M, Christophi RL, Jubelt B, Massa PT. Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients. Clin Immunol. 2012;142(3):308-19.
42. Kempuraj D, Selvakumar GP, Zaheer S, Thangavel R, Ahmed ME, Raikwar S, et al. Cross-Talk between Glia, Neurons and Mast Cells in Neuroinflammation Associated with Parkinson's Disease. J Neuroimmune Pharmacol. 2018;13(1):100-12.
43. Xu J, He X, Xu Y, Chen X, Li M, Zhang L, et al. Characteristics of systemic inflammation and brain iron deposition in Parkinson's disease patients. Ann Clin Transl Neurol. 2022;9(3):276-85.
44. Kempuraj D, Khan MM, Thangavel R, Xiong Z, Yang E, Zaheer A. Glia maturation factor induces interleukin-33 release from astrocytes: implications for neurodegenerative diseases. J Neuroimmune Pharmacol. 2013;8(3):643-50.
45. Chapuis J, Hot D, Hansmannel F, Kerdraon O, Ferreira S, Hubans C, et al. Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Mol psychiatry. 2009;14(11):1004-16.
46. Fu AK, Hung KW, Yuen MY, Zhou X, Mak DS, Chan IC, et al. IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline. Proc Natl Acad Sci U S A. 2016;113(19):E2705-13.
47. Xu J, He X, Xu Y, Chen X, Li M, Zhang L, et al. Characteristics of systemic inflammation and brain iron deposition in Parkinson's disease patients. Ann Clin Transl Neurol. 2022;9(3):276-85.
48. Lopetuso L, Chowdhry S, Pizarro T. Opposing Functions of Classic and Novel IL-1 Family Members in Gut Health and Disease. Front Immunol. 2013;4.
49. Zhu Y, Yuan M, Liu Y, Yang F, Chen WZ, Xu ZZ, et al. Association between inflammatory bowel diseases and Parkinson's disease: systematic review and meta-analysis. Neural Regen Res. 2022;17(2):344-53.
50. Harusato A, Abo H, Ngo VL, Yi SW, Mitsutake K, Osuka S, et al. IL-36γ signaling controls the induced regulatory T cell-Th9 cell balance via NFκB activation and STAT transcription factors. Mucosal Immunol. 2017;10(6):1455-67.
51. Li Q, Liu S, Li L, Ji X, Wang M, Zhou J. Spinal IL-36γ/IL-36R participates in the maintenance of chronic inflammatory pain through astroglial JNK pathway. Glia. 2019;67(3):438-51.
52. Alsahebfosoul F, Jahanbani-Ardakani H, Ghavimi R, Sedaghat N, Etemadifar M. Serum level of interleukin 36 in patients with multiple sclerosis. J Immunoassay Immunochem. 2018;39(5):558-64.
53. Hill MA, Gammie SC. Alzheimer’s disease large-scale gene expression portrait identifies exercise as the top theoretical treatment. Sci Reports. 2022;12(1):17189.
54. Liu G, Fiala M, Mizwicki MT, Sayre J, Magpantay L, Siani A, et al. Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am J Neurodegener Dis. 2012;1(1):60-74.
55. Tang J, Zeng X, Yang J, Zhang L, Li H, Chen R, et al. Expression and Clinical Correlation Analysis Between Repulsive Guidance Molecule a and Neuromyelitis Optica Spectrum Disorders. Front Immunol. 2022;13.
56. Moradi S, Zamani A, Mazdeh M, Ramezani M, Komaki A, Talebi-Ghane E, Eftekharian MM. An inclusive study on cytokine gene expression in Parkinson's disease: Advanced analysis using Bayesian regression model. Hum Immunol. 2023;84(2):123-9.
57. Fischer B, Kübelbeck TV, Kolb AL, Ringen J, Waisman A, Wittmann M, et al. IL-17A-driven psoriasis is critically dependent on IL-36 signaling. Front Immunol.14:1256133.
58. Mercurio L, Failla CM, Capriotti L, Scarponi C, Facchiano F, Morelli M, et al. Interleukin (IL)-17/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses. PLoS One. 2020;15(4):e0222969.
59. Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, Onofrj M. Peripheral cytokines profile in Parkinson's disease. Brain Behav Immun. 2009;23(1):55-63.
| Files | ||
| Issue | Vol 23 No 1 (2024) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijaai.v23i1.14955 | |
| Keywords | ||
| Interleukin-1 receptor accessory protein Interleukin-1 Interleukin-33 Interleukin-36 Parkinson disease | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Jafariaghdam N, Khoshmirsafa M, Zamani A, Talebi-Ghane E, Moradi S, Shahba F, Mazdeh M, Eftekharian MM. Different Gene Expression Patterns of IL-1 Family Members in Parkinson’s Disease: Results from Bayesian Regression Model. Iran J Allergy Asthma Immunol. 2024;23(1):69-81.
